SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0000950170-24-045978
Filing Date
2024-04-19
Accepted
2024-04-19 16:00:04
Documents
8
Period of Report
2024-06-20

Document Format Files

Seq Description Document Type Size
1 PRE 14A preliminary_filing_-_202.htm PRE 14A 605610
2 GRAPHIC img201639301_0.jpg GRAPHIC 3916
3 GRAPHIC img201639301_1.jpg GRAPHIC 3916
4 GRAPHIC img201639301_2.jpg GRAPHIC 23785
5 GRAPHIC img201639301_3.jpg GRAPHIC 23785
6 GRAPHIC img201639301_4.jpg GRAPHIC 23785
7 GRAPHIC img201639301_5.jpg GRAPHIC 666111
8 GRAPHIC img201639301_6.jpg GRAPHIC 294102
  Complete submission text file 0000950170-24-045978.txt   2037032
Mailing Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141
Business Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-40657 | Film No.: 24857633
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)